THOMSON REUTERS
CORTELLIS™

Durata Therapeutics Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 09-Jul-2013

THOMSON REUTERS
3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurateand validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

TABLE OF CONTENTS

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Durata Therapeutics Inc

COMPANY OVERVIEW

Company Name	Durata Therapeutics Inc
Parent Company Name	Durata Therapeutics Inc
Website	http://www.duratatherapeutics.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	13
Number of Patents as Owner	24
Number of Patents as Third Party	2
Number of Deals	11
Key Indications	Bacterial infection,Bacterial skin infection,Gram positive bacterium infection,MRSA infection,Streptococcus pneumoniae infection
Key Target-based Actions	Peptide deformylase inhibitor,N-acetylglucosamine deacetylase inhibitor,Unspecified enzyme inhibitor,Chondroitin sulfate synthase stimulator
Key Technologies	Small molecule therapeutic,Antibiotic,Oral formulation,Biological therapeutic,Dermatological formulation,Injectable formulation,Parenteral formulation unspecified,Peptide,Cell culture technique,Isolation technology

COMPANY PROFILE

SUMMARY

Durata Therapeutics Inc, a biopharmaceutical company, was formed in 2009 by a 5-member venture capital syndicate for the development of antibiotic programs to treat infectious diseases.

LOCATION

In November 2012, the company planned to relocate its corporate headquarters from Morristown, NJ, to Chicago, IL.

ACQUISITIONS & SPIN-OFFS

In December 2009, Durata acquired Vicuron Pharmaceuticals from Pfizer. The transaction was funded through a stock purchase by New Leaf Venture Partners, Domain Associates, Aisling Capital, Sofinnova Ventures and Canaan Partners. Durata obtained rights to dalbavancin and two undisclosed preclinical antibiotic programs.

FINANCIAL

In April 2013, Durata raised net proceeds of $54.1 million in an equity offering.

In April 2013, the company planned to raise the net proceeds of $46.3 million through an underwriiten public offering of 7.15 million shares of its common stock at $7 each. The underwritters were granted 30-day option to purchase additional shares up to 1,072,500 and the offering was expected to close on or about April 17, 2013; later that month, the public offering of 8,222,500 shares of common stock was closed.

In March 2013, the company entered into a US $20 million debt facility with Oxford Finance LLC; at that time, net proceeds were expected to be received by the end of that month.

In March 2012, Durata planned to conduct an IPO; in July 2012, the company priced 7.5 million shares of common stock at $9 each. The underwritters were granted 30-day option to purchase additional shares up to 1.125 million and the offering was expected to close on July 24, 2012. The company also reported that the shares would be traded on NASDAQ under the ticker symbol 'DRTX'; later that month, the IPO of 8.625 million common stock shares was closed before the underwriting discounts. By that time, a registration statement relating to these securities had been declared effective by the SEC; by September 2012, net proceeds of $73.9 million (approximately $71.4 million after the payment of $2.5 million of other offering expenses payable by the company) had been raised from the offering.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Drugs by Indication Table

Indication	Active	Inactive	Total
Infectious disease	3	11	14
Dermatological disease	1	2	3
Respiratory disease	1	0	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Discovery	2
Discontinued	2
No Development Reported	7

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	0	0	1	0	1
Drug - Asset Divestment	1	0	0	0	1
Drug - Early Research/Development	1	0	1	0	2
Drug - Development/Commercialization License	1	0	2	0	4
Drug - Manufacturing/Supply	0	0	3	0	3

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	0	23
Dermatological disease	0	9

Trials by Phase

Phase	Ongoing	All
Phase 3	0	7
Phase 2	0	7
Phase 1	0	5
Phase not specified	0	10

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Gastrointestinal disease	4	1	5
Degeneration	1	0	1
Immune disorder	0	1	1
Musculoskeletal disease	1	0	1
Genetic disorder	1	0	1
Metabolic disorder	1	0	1
Neurological disease	1	0	1
Respiratory disease	5	1	6
Infectious disease	26	2	28
Inflammatory disease	2	0	2

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Dermatological disease	4	0	4

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

dalbavancin

dalbavancin SNAPSHOT

Drug Name	dalbavancin
Key Synonyms	dalbavancin;Exulett;Zeven
Originator Company	Biosearch Italia SpA
Active Companies	Durata Therapeutics Inc
Inactive Companies	RaQualia Pharma Inc;Pfizer Inc;Vicuron Pharmaceuticals Inc;Biosearch Italia SpA
Highest Status	Phase 3 Clinical
Active Indications	Streptococcus pneumoniae infection;MRSA infection;Bacterial skin infection;Gram positive bacterium infection
Target-based Actions	
Other Actions	Antibacterial;Systemic dermatological antibacterial product;Bacterial cell wall synthesis inhibitor
Technologies	Intravenous formulation;Antibiotic;Glycoprotein;Infusion;Small molecule therapeutic
Last Change Date	21-May-2013

dalbavancin DEVELOPMENT PROFILE

SUMMARY

Durata Therapeutics, following its acquisition of Vicuron Pharmaceuticals (previously Versicor) from Pfizer, is developing dalbavancin (Zeven; Exulett; BI-397), a semisynthetic derivative of the natural glycopeptide A-40926 for the potential once-weekly iv treatment of complicated skin and soft tissue infections (cSSTI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA),.

In December 2004, Vicuron filed an NDA for cSSTI. An MAA was filed in July 2007 . However, in September 2008, Pfizer reported that it would withdraw its MAA and NDA and conduct an additional phase III trial, following feedback from regulatory authorities. Pfizer divested the drug to Durata in 2009. In March 2011, Durata began a phase III trial for acute bacterial skin and skin structure infections (ABSSSI) ; a second phase III trial began in September 2011. In December 2012, positive data from the DISCOVER-1 trial were reported ; in February 2013, positive topline data were reported from the DISCOVER-2 trial. In November 2012, the FDA granted dalbavancin Qualified Infectious Disease Product designation; at that time, Durata expected to launch the product in 2014. In January 2013, NDA and MAA filings were expected in the middle and end of 2013, respectively .

By October 2012, preclinical studies were also being carried out to potentially support clinical development of dalbavancin in streptococcal and staphylococcal pneumonia.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

The drug was previously being investigated for the treatment of catheter-related bloodstream infections. By January 2004, phase II trials had been completed ; however, in April 2006, Pfizer stated that it had no intention to conduct a phase III trial for this indication.

dalbavancin DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Durata Therapeutics Inc	Bacterial skin infection	Canada	Phase 3 Clinical	06-Sep-2012
Durata Therapeutics Inc	Bacterial skin infection	Europe	Phase 3 Clinical	06-Sep-2012
Durata Therapeutics Inc	Bacterial skin infection	US	Phase 3 Clinical	21-Dec-2009
Durata Therapeutics Inc	Gram positive bacterium infection	Canada	Phase 3 Clinical	06-Sep-2012
Durata Therapeutics Inc	Gram positive bacterium infection	Europe	Phase 3 Clinical	06-Sep-2012
Durata Therapeutics Inc	Gram positive bacterium infection	US	Phase 3 Clinical	21-Dec-2009
Durata Therapeutics Inc	MRSA infection	US	Phase 3 Clinical	21-Dec-2009
Durata Therapeutics Inc	MRSA infection	Japan	Discovery	21-Dec-2010
Durata Therapeutics Inc	Streptococcus pneumoniae infection	US	Discovery	18-Oct-2012
Biosearch Italia SpA	Gram positive bacterium infection	Italy	Discontinued	03-Mar-2003
Pfizer Inc	Bacterial skin infection	US	Discontinued	21-Dec-2009
Pfizer Inc	Gram positive bacterium infection	US	Discontinued	21-Dec-2009
Pfizer Inc	MRSA infection	US	Discontinued	21-Dec-2009
Pfizer Inc	Sepsis	US	Discontinued	24-Apr-2006
RaQualia Pharma Inc	MRSA infection	Japan	Discontinued	21-Dec-2010
Vicuron Pharmaceuticals Inc	Bacterial skin infection	US	Discontinued	14-Sep-2005
Vicuron Pharmaceuticals Inc	Gram positive bacterium infection	US	Discontinued	14-Sep-2005
Vicuron Pharmaceuticals Inc	MRSA infection	US	Discontinued	14-Sep-2005
Vicuron Pharmaceuticals Inc	Sepsis	US	Discontinued	14-Sep-2005

dalbavancin CHEMICAL STRUCTURES

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

CAS Registry Number:	Confidence Level:
171500-79-1	1

Name	Type
dalbavancin	INN
Zeven	Trade Name
MDL-63397	Research Code
BI-397	Research Code

CAS Registry Number:	Confidence Level:
148868-06-8	1



Name	Type
MDL-63246	Research Code

CAS Registry Number:	Confidence Level:
114894-40-5	1



Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Name	Type
Antibiotic A-40926 aglycone	

CAS Registry Number:	Confidence Level:
110882-83-2	1



Name	Type
Antibiotic A-40926A	

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

dalbavancin DRUG NAMES

Names	Type
Antibiotic A-40926 aglycone	
dalbavancin	INN
A-40926	Research Code
MDL-63246	Research Code
A-40926 analog, Versicor	
MDL-63042	Research Code, Analogue
VGE, Biosearch	
Exulett	Trade Name
V-glycopeptide	
Zeven	Trade Name
MDL-62476	Research Code, Analogue
BI-397	Research Code
MDL-63397	Research Code
Antibiotic A-40926A	
VGE, Vicuron	

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

dalbavancin SALES AND FORECASTS

CHARTS







Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

COMMENTARY

CONSENSUS SALES INFORMATION

Consensus forecast data for Durata Therapeutics are presented.

REGIONAL DEVELOPMENT AND MARKETING RIGHTS

In January 1999, Versicor Inc gained North American marketing rights from Biosearch Italia [311500]. In March 2003, Biosearch merged with Versicor to form Vicuron Pharmaceuticals [483671], and in June 2005, Pfizer acquired Vicuron, gaining dalbavancin development and marketing rights [480469], [607651]. In December 2009, Durata Therapeutics acquired Vicuron from Pfizer [1065287].

RaQualia Pharma (a spin-out of Pfizer) obtained the rights to dalbavancin in Japan from Pfizer in 2008. In December 2010, RaQualia Pharma signed a licensing agreement with Durata, granting Durata Japanese development and commercialization rights, meaning Durata owns full marketing rights worldwide [1170686], [1178040].

dalbavancin CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Gram positive bacterium infection											
0	0	0	0	0	1	0	2	0	4	0	7
Skin infection											
0	0	0	3	0	1	0	0	0	1	0	5
Bacterial skin infection											
0	0	0	3	0	0	0	0	0	1	0	4
Bacterial infection											
0	0	0	0	0	1	0	2	0	0	0	3
MRSA infection											
0	0	0	2	0	0	0	0	0	0	0	2
Staphylococcus aureus infection											
0	0	0	0	0	1	0	0	0	1	0	2
Staphylococcus infection											
0	0	0	0	0	0	0	1	0	0	0	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	5	0	3	0	4	0	10	0	22

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

dalbavancin DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Active Deals
Total: 3

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Durata Therapeutics Inc	0	0	3	0	3
RaQualia Pharma Inc	1	0	0	0	1
Pfizer Inc	1	0	0	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Drug - Early Research/Development	1	0	1
Drug - Manufacturing/Supply	1	0	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Durata Therapeutics Inc	4	0	4
Pfizer Inc	2	0	2
Chengdu Yacht Biotechnology Co Ltd	1	0	1
Protia LLC	1	0	1
The Medicines Company	1	0	1
Lepetit Pharma S.A.	1	0	1
Sanofi	1	1	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	3
Product	1
Process	1
Product (derivative)	1
Process (Intermediate)	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

pleuromutilins (bacterial infections), Durata

pleuromutilins (bacterial infections), Durata SNAPSHOT

Drug Name	pleuromutilins (bacterial infections), Durata
Key Synonyms	
Originator Company	Durata Therapeutics Inc
Active Companies	Durata Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Bacterial infection
Target-based Actions	
Other Actions	Antibacterial;Protein synthesis inhibitor
Technologies	Antibiotic;Small molecule therapeutic
Last Change Date	21-Mar-2013

pleuromutilins (bacterial infections), Durata DEVELOPMENT PROFILE

SUMMARY

Durata Therapeutics is investigating a series of pleuromutilins, that inhibit protein synthesis, for the potential treatment of bacterial infections. In December 2009, the program was in preclinical studies ; in August 2011, development was ongoing ; in March 2013, preclinical development was presumed to be ongoing.

pleuromutilins (bacterial infections), Durata DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Durata Therapeutics Inc	Bacterial infection	US	Discovery	21-Dec-2009

pleuromutilins (bacterial infections), Durata DRUG NAMES

Names	Type
antibiotics (bacterial infection), Durata	
pleuromutilins (bacterial infections), Durata	

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

lincosamide antibacterials, Durata

lincosamide antibacterials, Durata SNAPSHOT

Drug Name	lincosamide antibacterials, Durata
Key Synonyms	
Originator Company	Vicuron Pharmaceuticals Inc
Active Companies	Durata Therapeutics Inc
Inactive Companies	Vicuron Pharmaceuticals Inc
Highest Status	Discovery
Active Indications	Bacterial infection
Target-based Actions	
Other Actions	Bacterial protein synthesis inhibitor;Ribosome binding agent
Technologies	Antibiotic;Small molecule therapeutic
Last Change Date	21-Mar-2013

lincosamide antibacterials, Durata DEVELOPMENT PROFILE

SUMMARY

Durata Therapeutics, following its acquisition of Vicuron Pharmaceuticals (previously Versicor) from Pfizer, is investigating a series of lincosamide antibiotics for the potential treatment of bacterial infections. In August 2011, development was ongoing ; in March 2013, preclinical development was presumed to be ongoing.

Vicuron Pharmaceuticals was previously investigating VIC-105555 (VIC-5555), a lead from the series of lincosamide antibiotics for bacterial infections. In September 2004, Vicuron expected VIC-105555 to enter clinical trials in the first half of 2005 ; however, no further development was reported since the aquisition of Vicuron by Durata.

lincosamide antibacterials, Durata DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Durata Therapeutics Inc	Bacterial infection	US	Discovery	21-Dec-2009
Vicuron Pharmaceuticals Inc	Bacterial infection	US	Discontinued	30-Sep-2004

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

lincosamide antibacterials, Durata DRUG NAMES

Names	Type
bacterial protein synthesis inhibitors (ribosome binding), Pfizer	
VIC-5555	Research Code
lincosamide antibacterials, Pfizer	
VIC-105555	Research Code
VIC-105403	Research Code
VIC-105404	Research Code
lincosamide antibacterials, Durata	
lincosamide antibacterials, Vicuron	
bacterial protein synthesis inhibitors (ribosome-binding), Vicuron	

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:
http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

Return to Table of Contents